company background image
VYNE

VYNE Therapeutics NasdaqCM:VYNE Stock Report

Last Price

US$0.20

Market Cap

US$11.8m

7D

-10.3%

1Y

-85.3%

Updated

08 Dec, 2022

Data

Company Financials +
VYNE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

VYNE Stock Overview

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions.

VYNE Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for VYNE Therapeutics
Historical stock prices
Current Share PriceUS$0.20
52 Week HighUS$1.75
52 Week LowUS$0.19
Beta1.01
1 Month Change-24.96%
3 Month Change-30.14%
1 Year Change-85.32%
3 Year Changen/a
5 Year Changen/a
Change since IPO-98.65%

Recent News & Updates

Recent updates

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

Jul 02
Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Mar 19
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Dec 03
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07
Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

Feb 10
Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?

Jan 06
What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?

Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?

Dec 08
Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?

Shareholder Returns

VYNEUS PharmaceuticalsUS Market
7D-10.3%-0.3%-2.8%
1Y-85.3%14.1%-19.6%

Return vs Industry: VYNE underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.

Return vs Market: VYNE underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is VYNE's price volatile compared to industry and market?
VYNE volatility
VYNE Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: VYNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: VYNE's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200328Dave Domzalskihttps://www.vynetherapeutics.com

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.

VYNE Therapeutics Inc. Fundamentals Summary

How do VYNE Therapeutics's earnings and revenue compare to its market cap?
VYNE fundamental statistics
Market CapUS$11.76m
Earnings (TTM)-US$63.68m
Revenue (TTM)US$14.57m

0.8x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VYNE income statement (TTM)
RevenueUS$14.57m
Cost of RevenueUS$3.35m
Gross ProfitUS$11.22m
Other ExpensesUS$74.90m
Earnings-US$63.68m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.10
Gross Margin77.02%
Net Profit Margin-437.10%
Debt/Equity Ratio0.0%

How did VYNE perform over the long term?

See historical performance and comparison